TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00977457

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study: NCT02796755

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants randomized to this arm will take a placebo, that matches the appearance of 100 mg tablets of riluzole, daily for 8 weeks.
Study: NCT03628027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerised decision support algorithm
Description: The algorithm is integrated into the EMIS computer system used by GPs. The algorithm advises on which antidepressants should be prescribed based on a patient's treatment history.
Study: NCT00778973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline 100 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline 100 mg tablets
Study: NCT02921061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV
Study: NCT04218565

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab (GOL)
Description: Patients with refractory BD associated uveitis will receive Golimumab therapy, the efficacy and corticosteroids-sparing effects will be evaluated.
Study: NCT02166671

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV booster vaccination 1dose
Study: NCT02012868

Intervention type: PROCEDURE
Intervention: bariatric surgery
Study: NCT00430183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m\^2 will be administered intravenously over one hour on Day 1 of each cycle, every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH agonist
Description: Given intramuscularly

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Patients undergo radical prostatectomy with staging pelvic lymphadenectomy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery
Description: Patients undergo radical prostatectomy with staging pelvic lymphadenectomy.
Study: NCT03965000

Intervention type: OTHER
Intervention: Mixed-meal-tolerance-test
Description: To assess the dynamics of the glucagon-incretin axis we need to perform the MMTT. Thereby the patients need to consume a body weight adjusted, standardized meal and we draw blood at fixed time points over 4 hours.

Intervention type: OTHER
Intervention: Mixed-meal-tolerance-test
Description: To assess the dynamics of the glucagon-incretin axis we need to perform the MMTT. Thereby the patients need to consume a body weight adjusted, standardized meal and we draw blood at fixed time points over 4 hours.
Study: NCT03986073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-F3083 capsule 10 mg
Description: Subjects in the low dose group administrated TQ-F3083 capsule 10mg, once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-F3083 capsule 20 mg
Description: Subjects in the high dose group administrated TQ-F3083 capsule 20 mg, once daily for 12 weeks.
Study: NCT02023853

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erythritol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole gel
Study: NCT03752528

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: Determination of buprenorphine and norbuprenorphine plasma concentrations
Study: NCT03986073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-F3083 blank analog capsule
Description: Subjects administrated one TQ-F3083 blank analog capsule orally, once daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQ-F3083 blank analog capsule
Description: Subjects administrated two TQ-F3083 blank analog capsules orally, once daily for 12 weeks.
Study: NCT03986073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQ-F3083 blank analog capsule
Description: Subjects administrated two TQ-F3083 blank analog capsules orally, once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin blank analog tablet
Description: Subjects administrated one Linagliptin blank analog tablet orally, once daily for 12 weeks.
Study: NCT03752528

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine sample collection
Description: Urine sample for determination of free buprenorphine and free norbuprenorphine concentrations, qualitative UDS for opioids, quantitative UDS for buprenorphine, norbuprenorphine and naloxone, and determination of creatinine concentration

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine sample collection
Description: Urine sample for determination of free buprenorphine and free norbuprenorphine concentrations, qualitative UDS for opioids, quantitative UDS for buprenorphine, norbuprenorphine and naloxone, and determination of creatinine concentration
Study: NCT01437501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broccoli Sprout Extract Beverage
Description: Broccoli Sprout Extract Beverage: 600 micromole glucoraphanin and 40 micromole sulforaphane dissolved in 100 mL dilute pineapple and lime juice daily for 84 days.
Study: NCT02856165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal canula oxygen therapy
Description: High-flow nasal canula oxygen therapy (HNF) using Optiflow junior system and AIRVO2 turbine (F\&P, NZ) at initial flow to 3l/kg/min (up to a maximum of 20l/min), FiO2 adjusted for SpO2 \> 94%.
Study: NCT01437501

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo beverage
Description: 100 mL of dilute pineapple and lime juice daily for 84 days.
Study: NCT03986073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin blank analog tablet
Description: Subjects administrated one Linagliptin blank analog tablet orally, once daily for 12 weeks.
Study: NCT02096718

Intervention type: DRUG
Group type: OTHER
Intervention: Afatinib healthy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib severe renally impaired

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib moderate renally impaired
Study: NCT03834883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
Study: NCT02856165

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-flow oxygen therapy with standard nasal canula
Description: flow adjusted to SpO2 \> 94% (up to a maximum of 2l/min).
Study: NCT00675025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil hydrochloride (Aricept)
Description: Liquid form Aricept - 5 mg/5 mL donepezil hydrochloride.
Study: NCT06160401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Singletine
Description: Singletine orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Singletine
Description: Singletine orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally administered
Study: NCT03986073

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Linagliptin blank analog tablet
Description: Subjects administrated one Linagliptin blank analog tablet orally, once daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin tablet
Description: Subjects in the positive drug control group administrated one Linagliptin tablet orally, once daily for 12 weeks.
Study: NCT03834883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibutilide
Description: Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibutilide
Description: Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibutilide
Description: Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibutilide
Description: Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
Study: NCT06160401

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally administered
Study: NCT03411330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronidase
Description: Scalp nerves block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum allowed dose 175 mg in group A, Hyaluronidase will be added in group H in a dose of 1500 IU (The minimum and maximum effective doses of hyaluronidase are not known. The doses used range from0.75 IU/ml to 300 IU/ml
Study: NCT01845545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early provision of microfinance
Description: The CPSL staff will support the formation of the self-help groups from the start of the study. The women in this group will have access to microfinance from the first 18 months of the study and will be eligible for emergency loans (up to Rs3000) and general purpose loans, (Rs50-3000) after 3-6 months of starting the self-help group.
Study: NCT02487108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-46763
Description: TV-46763 will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-46763
Description: TV-46763 will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-46763
Description: TV-46763 will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to TV-46763 will be administered per schedule specified in the arm description.
Study: NCT03889587

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Innervation
Description: There will be simultaneous innervation of vascularized iliac or fibular bone flaps through neurorrhaphy between the nerves innervating iliac or fibular bones and recipient site.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-innervation
Description: This will be the traditional method of vascularized iliac or fibular bone flaps, and neurorrhaphy will not be performed.
Study: NCT01589484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SWL - Compact Delta Dornier Med Tech
Description: All patients will be submitted to a noncontrast computed tomography before to SWL. Patients will be submitted to SWL under the following conditions: outpatient, general anesthesia, 3000 impulses, rate of 90/min, discharged from hospital in the same day with alpha-blocker (doxazosin) during 30 days.
Study: NCT01880411

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEK Fusion Protein Vaccine
Description: PEK (PE-E7-K3), a recombinant protein combined with GPI-0100 adjuvant
Study: NCT03411330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: bupivacaine (0.5%)
Study: NCT00311298

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multimicronutrients
Description: Randomised, double-blind trial among pulmonary TB patients, except those who are found to be sputum positive and HIV positive. Both arms received a daily biscuit weighing 30 g (4.5 g protein, 615 kJ). The biscuit given to the No micronutrient-arm contained no additional micronutrients. The biscuit given to the Micronutrient-arm contained the following micronutrients: vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg. The intervention was given for 60 days during initial TB treatment.
Study: NCT03411330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: bupivacaine (0.5%)
Study: NCT03447860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAACC
Description: Mindfulness based caregiver intervention that includes education , problem solving, skill building, stress management and mindfulness to help enhance compassion and acceptance of self and others

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: REACH-VA
Description: A cognitive-behavior based multi-component caregiver intervention to reduce caregiver stress
Study: NCT02030353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-regulation plus activity monitoring
Description: Individual in-person session, digital smart scale, online intervention, and an activity monitor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-regulation
Description: Individual in-person session, digital smart scale, and online intervention.
Study: NCT01327690

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT (Cognitive Behavior Therapy)
Description: CBT group therapy sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFT (Emotional Freedom Techniques)
Description: Group therapy sessions using EFT
Study: NCT01423526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP10292
Description: Drug: DWP10292 tablets, oral administration, single administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, oral administration, single administrations
Study: NCT00311298

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Multimicronutrients
Description: Randomised, double-blind trial among pulmonary TB patients, except those who are found to be sputum positive and HIV positive. Both arms received a daily biscuit weighing 30 g (4.5 g protein, 615 kJ). The biscuit given to the No micronutrient-arm contained no additional micronutrients. The biscuit given to the Micronutrient-arm contained the following micronutrients: vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg. The intervention was given for 60 days during initial TB treatment.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Energy and proteins
Description: Randomised, single-blind trial among sputum-positive HIV-coinfected pulmonary TB patients. Both arms received a daily for biscuit weighing 30 g (4.5 g protein, 615 kJ), with micronutrients (vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg). The experimental arm received an additional 5 biscuits without additional micronutrients. Thus, both arms received the same amount of micronutrients. However, the intervention arm received 3690 kJ and 27 g protein per day, while the control arm received 615 kJ and 4.5 g protein. The intervention was given for 60 days during initial TB treatment.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy and proteins
Description: Randomised, single-blind trial among sputum-positive HIV-coinfected pulmonary TB patients. Both arms received a daily for biscuit weighing 30 g (4.5 g protein, 615 kJ), with micronutrients (vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg). The experimental arm received an additional 5 biscuits without additional micronutrients. Thus, both arms received the same amount of micronutrients. However, the intervention arm received 3690 kJ and 27 g protein per day, while the control arm received 615 kJ and 4.5 g protein. The intervention was given for 60 days during initial TB treatment.
Study: NCT02143050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT04869748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perfetti method
Description: * Participant was blindfolded, while lying flat in a quiet and comfortable room.~* Participants received a 15-minute session of Perfetti method on affected elbow flexor.~* Participants were asked to concentrate on the position of their elbows.~* Protocol has 4 steps of training starting from 2 positions; full flexion and full extension 3 positions; full flexion, elbow flexion 90 degree and full extension 4 positions; full flexion, elbow flexion 110-140 degree, elbow flexion 45-60 degree and full extension 5 positions; full flexion, elbow flexion 110-140 degree, elbow flexion 90 degree, elbow flexion 45-60 degree and full extension of elbow.~* After therapist passively moved elbow joint to a position, participant guessed the position of his/her elbow. If the answers were correct consecutively for 10 times, the therapist increased the number of positions according to the protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: passive stretching
Description: * Participant was blindfolded, while lying flat in a quiet and comfortable room.~* Each participant received gentle passive stretching of elbow flexor and maintained in full elbow extension position for 15 minutes.
Study: NCT00574964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gliadel Wafer, Temodar and Radiotherapy
Description: Given concurrently starting 10-30 days after surgery.
Study: NCT03635671

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography Angiography
Description: Retinal scans will be acquired at each follow up visit

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography Angiography
Description: Retinal scans will be acquired at each follow up visit
Study: NCT00104598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Abstinence Program
Description: This investigation was a randomized controlled study of two framed message conditions for smoking cessation in combination with open label bupropion SR (300 mg/day). Two hundred fifty-eight cigarette smokers were randomly assigned to receive either gain- or loss-framed video and printed messages encouraging smoking abstinence. Preproduced video and printed information were chosen as the intervention media because of their reliability in delivering specific framed messages. All participants were seen at a community mental health center for 6 months and received a 7-week supply of bupropion SR.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Abstinence Program
Description: This investigation was a randomized controlled study of two framed message conditions for smoking cessation in combination with open label bupropion SR (300 mg/day). Two hundred fifty-eight cigarette smokers were randomly assigned to receive either gain- or loss-framed video and printed messages encouraging smoking abstinence. Preproduced video and printed information were chosen as the intervention media because of their reliability in delivering specific framed messages. All participants were seen at a community mental health center for 6 months and received a 7-week supply of bupropion SR.
Study: NCT01403948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836826
Description: Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion
Study: NCT04957433

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Specimen
Description: Blood and Sputum Specimen Samples

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Specimen
Description: Blood and Sputum Specimen Samples

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Specimen
Description: Blood and Sputum Specimen Samples

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Specimen
Description: Blood and Sputum Specimen Samples
Study: NCT02991989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Snacking
Description: Each bout of exercise snacking consists of 5 exercise. Each exercise is performed for one minute, with aim of completing as many repetitions as possible of that exercise in that minute. One minute of rest is observed between each exercise of the exercise snack. The five exercises are; sit-to-stand from a chair, marching on the spot, seated knee extensions alternating legs, standing knee bends alternating legs, and standing calf raises. The sit-to-stand exercise is always performed first, with the number of repetitions achieved recorded, and subsequent exercises performed in any order without recording of repetitions.~Two exercise snacks are completed each day for 28 days; once in the morning and once in the evening, or at least separated by 2 hours.
Study: NCT02471157

Intervention type: OTHER
Intervention: Observation

Intervention type: OTHER
Intervention: Observation
Study: NCT03104842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Antibody Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Antibody Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Capsel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Capsel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Capsel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Capsel